SG11202003700TA - Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) - Google Patents

Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)

Info

Publication number
SG11202003700TA
SG11202003700TA SG11202003700TA SG11202003700TA SG11202003700TA SG 11202003700T A SG11202003700T A SG 11202003700TA SG 11202003700T A SG11202003700T A SG 11202003700TA SG 11202003700T A SG11202003700T A SG 11202003700TA SG 11202003700T A SG11202003700T A SG 11202003700TA
Authority
SG
Singapore
Prior art keywords
hbv
hepatitis
virus
novel
carboxamides
Prior art date
Application number
SG11202003700TA
Inventor
Alastair Donald
Andreas Urban
Susanne Bonsmann
Anita Wegert
Christiaan Gremmen
Jasper Springer
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of SG11202003700TA publication Critical patent/SG11202003700TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202003700TA 2017-11-02 2018-11-02 Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) SG11202003700TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17199687 2017-11-02
PCT/EP2018/000502 WO2019086141A1 (en) 2017-11-02 2018-11-02 Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)

Publications (1)

Publication Number Publication Date
SG11202003700TA true SG11202003700TA (en) 2020-05-28

Family

ID=60201941

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003700TA SG11202003700TA (en) 2017-11-02 2018-11-02 Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)

Country Status (23)

Country Link
US (1) US11267825B2 (en)
EP (1) EP3704127A1 (en)
JP (1) JP2021501764A (en)
KR (1) KR20200083551A (en)
CN (1) CN111448199A (en)
AR (1) AR113826A1 (en)
AU (1) AU2018361364B2 (en)
BR (1) BR112020008762A2 (en)
CA (1) CA3081386A1 (en)
CL (1) CL2020001145A1 (en)
CU (1) CU20200037A7 (en)
EA (1) EA202091113A1 (en)
EC (1) ECSP20029558A (en)
GE (1) GEP20227373B (en)
IL (1) IL274298A (en)
MA (1) MA50524A (en)
MX (1) MX2020004839A (en)
PH (1) PH12020550525A1 (en)
SG (1) SG11202003700TA (en)
TW (1) TW201930315A (en)
UY (1) UY37962A (en)
WO (1) WO2019086141A1 (en)
ZA (1) ZA202002249B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38434A (en) * 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PIRAZIN INDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
UY38436A (en) * 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PYRAZININDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
SG11202111236UA (en) * 2019-04-30 2021-11-29 Aicuris Gmbh & Co Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
KR20230124583A (en) 2020-11-23 2023-08-25 이난타 파마슈티칼스, 인코포레이티드 Novel spiropyrrolidine-derived antiviral agent
WO2022235605A1 (en) 2021-05-04 2022-11-10 Enanta Pharmaceuticals, Inc. Novel macrocyclic antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023086352A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2023086350A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
WO2023107419A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
WO2023137007A1 (en) * 2022-01-11 2023-07-20 Enanta Pharmaceuticals, Inc. Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998040385A1 (en) 1997-03-07 1998-09-17 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
DE19817264A1 (en) 1998-04-18 1999-10-21 Bayer Ag New dihydropyrimidine derivatives and their corresponding mesomers useful as antiviral agents
AU4289100A (en) 1999-03-25 2000-10-16 Bayer Aktiengesellschaft Dihydropyrimidines and their use in the treatment of hepatitis
AU3009801A (en) 1999-12-22 2001-07-03 Bayer Aktiengesellschaft Combinations of medicaments for treating viral diseases
DE10012823A1 (en) 2000-03-16 2001-09-20 Bayer Ag New alkyl-6-aminoalkyl-dihydropyrimidine-5-carboxylate derivatives, useful for the treatment of viral, especially hepatitis B, infections
ES2679744T3 (en) 2003-11-12 2018-08-30 Daiichi Sankyo Company, Limited Procedure to produce thiazole derivatives
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
AU2007225273A1 (en) 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
UY30867A1 (en) 2007-01-12 2008-09-02 Astrazeneca Ab NEW ANALOGS OF PIRIDINA VII 543
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
US8024013B2 (en) 2008-07-09 2011-09-20 Sony Ericsson Mobile Communications Ab Regulating power duty cycle of an RF transmitter/receiver responsive to distance moved
EP2327704A4 (en) 2008-08-29 2012-05-09 Shionogi & Co Ring-fused azole derivative having pi3k-inhibiting activity
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US9090632B2 (en) 2010-08-31 2015-07-28 Vanderbilt University Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors
MX354852B (en) 2010-09-02 2018-03-22 Suven Life Sciences Ltd Star Heterocyclyl compounds as histamine h3 receptor ligands.
EP2720695A4 (en) 2011-06-15 2014-11-12 Nono Inc Agents and methods for treating ischemic and other diseases
WO2013006394A1 (en) 2011-07-01 2013-01-10 Institute For Hepatitis And Virus Research Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
AP2014007621A0 (en) 2011-11-11 2014-05-31 Pfizer 2-Thiopyrimidinones
CA2857344C (en) 2011-12-21 2019-02-12 Novira Therapeutics, Inc. Hepatitis b antiviral agents
EP2800742B1 (en) 2012-01-06 2016-04-06 Janssen Sciences Ireland UC 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b
SG10201605291WA (en) 2012-08-28 2016-08-30 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
ES2610758T3 (en) 2012-08-28 2017-05-03 Janssen Sciences Ireland Uc Condensed bicyclic sulfamoyl derivatives and their use as medicines in the treatment of hepatitis B
WO2014113191A1 (en) 2013-01-15 2014-07-24 Xiaohu Zhang Hedgehog pathway signaling inhibitors and therapeutic applications thereof
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
EA201592126A1 (en) 2013-05-17 2016-05-31 Ф. Хоффманн-Ля Рош Аг 6-BRIDGED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
WO2014184365A1 (en) 2013-05-17 2014-11-20 Janssen R&D Ireland Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
TR201807090T4 (en) 2013-07-25 2018-06-21 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and its use as medicaments for the treatment of hepatitis.
ES2739435T3 (en) 2013-10-18 2020-01-31 Univ Indiana Res & Tech Corp Hepatitis B viral assembly effectors
EA201690979A1 (en) 2013-11-14 2016-08-31 Новира Терапьютикс, Инк. AZEPAN DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
BR112016020566B1 (en) 2014-03-07 2022-11-29 F. Hoffmann-La Roche Ag NOVEL HETEROARYL-DIHYDRO-PYRIMIDINES FUSED IN POSITION 6 FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION
KR102363174B1 (en) 2014-03-13 2022-02-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 Hepatitis b core protein allosteric modulators
KR20160133563A (en) 2014-03-28 2016-11-22 선샤인 레이크 파르마 컴퍼니 리미티드 Dihydropyrimidine compounds and their application in pharmaceuticals
EP3139954A4 (en) 2014-05-09 2018-02-28 Indiana University Research and Technology Corporation Methods and compositions for treating hepatitis b virus infections
RU2664329C1 (en) 2014-08-14 2018-08-16 Ф. Хоффманн-Ля Рош Аг Novel piridazones and triazinones for treatment and preventing of hepatitis b virus infection
DK3227262T3 (en) 2014-12-02 2020-08-10 Novira Therapeutics Inc SULFIDALKYL AND PYRIDYL-REVERSE SULPHONAMIDE COMPOUNDS FOR HBV TREATMENT
CN107531691A (en) 2014-12-30 2018-01-02 诺维拉治疗公司 Treat the derivative and method of hepatitis B infection
MA41338B1 (en) 2015-01-16 2019-07-31 Hoffmann La Roche Pyrazine compounds for the treatment of infectious diseases
CA2979490C (en) 2015-03-16 2023-07-18 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
MX2017011997A (en) * 2015-03-18 2018-05-28 Abide Therapeutics Inc Piperazine carbamates and methods of making and using same.
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016177655A1 (en) 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CN107849037B (en) 2015-07-21 2020-04-17 豪夫迈·罗氏有限公司 Tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infection
WO2017015451A1 (en) 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
TWI730985B (en) 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 Hepatitis b core protein modulators
CA3000197A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
CA3004147C (en) 2015-11-04 2019-09-10 Qilu Pharmaceutical Co., Ltd. Crystal form, preparation method and intermediate of dihydropyrido ring compound
WO2017136403A1 (en) 2016-02-02 2017-08-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CA3017020C (en) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
JP6957518B2 (en) 2016-05-20 2021-11-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft A novel pyrazine compound with oxygen, sulfur and nitrogen linkers for the treatment of infectious diseases
WO2018011160A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
CN109415368B (en) 2016-07-14 2021-04-30 豪夫迈·罗氏有限公司 Carboxy 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazine compounds for the treatment of infectious diseases
EP3484886B1 (en) 2016-07-14 2020-03-04 Hoffmann-La Roche AG 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
CA3036245C (en) 2016-09-13 2021-07-20 Arbutus Biopharma Corporation Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
JOP20190105A1 (en) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc Magl inhibitors
MX2019010404A (en) 2017-03-02 2019-11-21 Assembly Biosciences Inc Cyclic sulfamide compounds and methods of using same.
MA49014A (en) 2017-03-21 2020-02-05 Arbutus Biopharma Corp DIHYDROINDENE-4-CARBOXAMIDES SUBSTITUTED, THEIR ANALOGUES AND PROCESSES FOR THEIR CORRESPONDING USE
CA3081399A1 (en) * 2017-11-02 2019-05-09 Aicuris Gmbh & Co. Kg Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)

Also Published As

Publication number Publication date
CN111448199A (en) 2020-07-24
ECSP20029558A (en) 2020-07-31
AR113826A1 (en) 2020-06-17
CU20200037A7 (en) 2021-03-11
GEP20227373B (en) 2022-04-25
US11267825B2 (en) 2022-03-08
WO2019086141A1 (en) 2019-05-09
IL274298A (en) 2020-06-30
BR112020008762A2 (en) 2020-10-20
MA50524A (en) 2020-09-09
AU2018361364B2 (en) 2020-11-26
JP2021501764A (en) 2021-01-21
PH12020550525A1 (en) 2021-04-26
MX2020004839A (en) 2020-10-16
US20200354379A1 (en) 2020-11-12
EP3704127A1 (en) 2020-09-09
WO2019086141A8 (en) 2019-08-29
AU2018361364A1 (en) 2020-05-21
CL2020001145A1 (en) 2020-10-09
EA202091113A1 (en) 2020-08-28
KR20200083551A (en) 2020-07-08
UY37962A (en) 2019-05-31
ZA202002249B (en) 2022-01-26
TW201930315A (en) 2019-08-01
CA3081386A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
SG11202003746UA (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
ZA202002249B (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
HK1255847A1 (en) Vaccines against hepatitis b virus
HK1251219A1 (en) Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
IL267949A (en) Altered virus
EP3360554A4 (en) Anti-hepatitis b virus agent
EP3325097A4 (en) Compositions and agents against hepatitis b virus and uses thereof
EP3283472A4 (en) Hepatitis b viral assembly effectors
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
EP3675637A4 (en) Hepatitis b antiviral agents
IL275427A (en) Hepatitis b virus (hbv) vaccines and uses thereof
IL265921A (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
IL267785A (en) Virus
IL290924A (en) Hepatitis b virus vaccines
IL266526A (en) Recombinant virus, composition comprising the same, and uses thereof
IL287278A (en) Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
EP3775292A4 (en) Virus bioresistors
IL287227A (en) Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
EP3615054A4 (en) NUCLEOSIDE-MODIFIED mRNA-LIPID NANOPARTICLE LINEAGE VACCINE FOR HEPATITIS C VIRUS
EP3862004A4 (en) Anti-hepatitis b virus agent
IL287269A (en) Novel oxalyl piperazines active against the hepatitis b virus (hbv)
GB201813175D0 (en) Virus use
EP3621645A4 (en) Bivalent dengue/hepatitis b vaccines
GB201702193D0 (en) Hepatitis E virus vaccine
GB201716047D0 (en) Virus